Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19-Reference-Cited by-同舟云学术

Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19

Published:2023-01 Issue:1 Volume:23 Page:35-45
ISSN:1871-5303
Container-title:Endocrine, Metabolic & Immune Disorders - Drug Targets
language:en
Short-container-title:EMIDDT

Author:

Alexiou Athanasios¹²,Batiha Gaber El-Saber³,Al-Kuraishy Hayder M.⁴,Al-Gareeb Ali I.⁴,Al-Harcan Nasser A. Hadi⁵

Affiliation:

1. Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, Australia

2. AFNP Med Austria, Wien, Austria

3. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt

4. Department of Clinical Pharmacology and Medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq

5. Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Rasheed University College, Baghdad, Iraq

Abstract

Abstract: Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.

Publisher

Bentham Science Publishers Ltd.

Subject

Immunology and Allergy,Endocrinology, Diabetes and Metabolism

Reference95 articles.

1. Al-Kuraishy H.M.; Al-Gareeb A.I.; Alzahrani K.J.; Cruz-Martins N.; Batiha G.E.; The potential role of neopterin in Covid-19: A new perspective. Mol Cell Biochem 2021,476(11),4161-4166

2. Al-Kuraishy H.M.; Al-Gareeb A.I.; Alzahrani K.J.; Alexiou A.; Batiha G.E.; Niclosamide for COVID-19: Bridging the gap. Mol Biol Rep 2021,48(12),8195-8202

3. Al-Kuraishy H.M.; Al-Gareeb A.I.; Alblihed M.; Cruz-Martins N.; Batiha G.E.; COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: The anti-inflammatory role of metformin. Front Med (Lausanne) 2021,8,644295

4. Al-Kuraishy H.M.; Al-Gareeb A.I.; Qusty N.; Cruz-Martins N.; El-Saber Batiha G.; Sequential doxycycline and colchicine combination therapy in COVID-19: The salutary effects. Pulm Pharmacol Ther 2021,67,102008

5. Al-Kuraishy H.M.; Al-Gareeb A.I.; Qusty N.; Alexiou A.; Batiha G.E.; Impact of sitagliptin in non-diabetic COVID-19 patients. Curr Mol Pharmacol 2022,15(4),683-692

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The possible role of nuclear factor erythroid‐2‐related factor 2 activators in the management of Covid‐19;Journal of Biochemical and Molecular Toxicology;2023-12-09

2. The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review;Cancer Reports;2023-11-28

3. SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway;Cell Stress and Chaperones;2023-11

4. Changes in the Fibrinolytic System of Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2;Journal of Clinical Medicine;2023-08-10

5. Possible role of LCZ696 in atherosclerosis: new inroads and perspective;Molecular and Cellular Biochemistry;2023-08-01